A CLDN18.2‐Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer

A CLDN18.2‐Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer

Abstract Precision treatment of gastric cancer requires specific biomarkers, and CLDN18.2 emerges as a promising target for patients’ stratification and therapeutic guidance. In 563 cases, 54.4% of patients are identified as CLDN18.2‐positive, with CLDN18.2 expression negatively correlated with immu...

Full description

Saved in:
Bibliographic Details
Main Authors: Xueying Wang, Hui Hui, Jing Han, Ting Guo, Yiding Wang, Lin Meng, Cong Chen, Jie He, Xiaoyong Guo, Fuyu Zhong, Hong Du, Jie Tian, Xiaofang Xing, Yang Du, Jiafu Ji
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Advanced Science
Subjects:
CLDN18.2
gastric cancer
immunotherapy
magnetic hyperthermia
molecular imaging
nanoparticle
Online Access:https://doi.org/10.1002/advs.202413913
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Precision treatment of gastric cancer requires specific biomarkers, and CLDN18.2 emerges as a promising target for patients’ stratification and therapeutic guidance. In 563 cases, 54.4% of patients are identified as CLDN18.2‐positive, with CLDN18.2 expression negatively correlated with immune‐related factors like PD‐L1, indicating a “cold” tumor microenvironment. Here, a novel CLDN18.2 monoclonal antibody 1D5 is created with superior high specificity and affinity, and the antibody‐dependent fluorescence‐magnetic nanoparticle is developed for specific detection and magnetic hyperthermia (MHT). Under the assistance of sensitive fluorescence and deep‐penetrating magnetic particle imaging for tracing and timing the optimal nanoparticle dosage, MHT induces robust immunogenic response via DNA mismatch repair and tumor‐associated antigen release. It recruits CD11c+ dendritic cells, compensates PD‐1 in CD8+ T cells, and enhances CD86+ macrophage polarization. The combination of anti‐PD‐1 therapy increased TNF‐α and IFN‐γ secretion and further boosted the cytotoxic efficacy of CD8+ T cells. Excellent therapeutic efficacy is found simultaneously on cell‐derived allografts and patient‐derived xenografts based on this spatiotemporally manipulated strategy, presenting a therapeutic option for enhancing responsiveness to immunotherapy for CLDN18.2‐positive individuals.
ISSN:2198-3844

Similar Items